United Services Automobile Association Invests $472,000 in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• The United Services Automobile Association acquired 3,840 shares of Jazz Pharmaceuticals PLC, valued at approximately $472,000.
• Institutional investors and hedge funds now own 89.14% of Jazz Pharmaceuticals' stock, indicating strong interest from major financial players.
• Jazz Pharmaceuticals reported a quarterly loss of ($8.25) earnings per share, missing analysts' expectations, while also achieving revenue of $1.05 billion.

United Services Automobile Association acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,840 shares of the specialty pharmaceutical company's stock, valued at approximately $472,000.

Several other large investors have also made changes to their positions in JAZZ. Nuveen LLC acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at $62,362,000. Fuller & Thaler Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock valued at $165,245,000 after purchasing an additional 391,660 shares during the period. Perpetual Ltd grew its position in shares of Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock valued at $118,212,000 after purchasing an additional 357,784 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after purchasing an additional 293,360 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock worth $43,652,000 after purchasing an additional 209,667 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Down 1.8%

Shares of JAZZ stock traded down $2.30 on Friday, hitting $126.16. 559,937 shares of the stock traded hands, compared to its average volume of 682,018. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The firm's 50-day moving average price is $118.59 and its two-hundred day moving average price is $116.54. The stock has a market capitalization of $7.65 billion, a PE ratio of -18.75, a PEG ratio of 7.97 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. During the same period last year, the firm earned $5.30 earnings per share. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price objective on the stock. Morgan Stanley lifted their price target on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. The Goldman Sachs Group lifted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research note on Friday, August 29th. Finally, Royal Bank Of Canada upped their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $178.67.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the sale, the director owned 429,973 shares of the company's stock, valued at $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.